Genomtec S.A. plans to debut on the NewConnect market by the end of 2020. The company predict that the commercialization of Genomtec ID will take place in the first half of 2022.
Genomtec is a producer of mobile molecular analyzers. The company’s flagship project is the Genomtec ID mobile diagnostic system, which allows to short up the diagnostic process up to 15 minutes. The company is finalizing the beta system of the control device and the production microflow card. It also developed tests for the detection of 5 pathogens, four of which have patent applications. In addition to the SARS-CoV-2 tests, the test kits developed by Genomtec allow the diagnosis of HPV (human papillomavirus) both types – 16 and 18; bacteria often responsible for atypical pneumonia in children, as well as the bacteria Borrelia burgdorferi, which causes Lyme disease.
Genomtec sees the potential to use Genomtec’s technology to the fast identification of cancer mutations or predisposing to cancer disease and for screening tests. As a result, the implementation of effective treatment will be much quicker.